ArticleFrontiers in pharmacology2026
Autologous cutis and subcutis micrografts combined with a collagen-elastin dermal scaffold for chronic wounds: a retrospective single-arm clinical study with prospectively collected data.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chronic wounds remain a significant clinical challenge, characterised by sustained inflammation, impaired angiogenesis, and defective extracellular matrix remodelling. Autologous cutis and subcutis micrografts and collagen-elastin dermal scaffolds have each shown promise in wound healing, but their combination has not been previously investigated in a clinical study. This study aimed to evaluate the feasibility, safety, and preliminary effectiveness of autologous cutis and subcutis micrografts seeded onto a collagen-elastin dermal scaffold for the treatment of chronic wounds. Methods: A single-arm, single-centre, retrospective analysis of prospectively collected data was conducted. Forty-four patients with chronic wounds were screened; 34 met the eligibility criteria and received the intervention. Following surgical debridement, autologous cutis and subcutis tissue was harvested by punch biopsies and mechanically disaggregated to produce a micrograft suspension, which was used to imbibe a collagen-elastin dermal scaffold before application to the wound bed. The primary outcome was percentage reduction in wound surface area at day 90, measured by digital planimetry. Secondary outcomes included complete wound closure rate, Bates-Jensen Wound Assessment Tool (BWAT) scores, wound bed tissue composition, patient-reported outcomes (pain Visual Analogue Scale, Wound-QoL, EQ-5D-5L), systemic inflammatory markers (C-reactive protein, erythrocyte sedimentation rate, neutrophil-to-lymphocyte ratio), nutritional markers (albumin, prealbumin), and adverse events. Assessments were performed at baseline and at days 7, 14, 30, 60, and 90. Results: Thirty-four patients (mean age 62.8 ± 11.6 years; 58.8% male) were treated. Wound aetiologies included venous (35.3%), diabetic (26.5%), mixed arteriovenous (17.6%), pressure (11.8%), and post-surgical (8.8%) ulcers. The mean baseline wound surface area was 13.2 ± 9.1 cm Conclusion: The combination of autologous cutis and subcutis micrografts with a collagen-elastin dermal scaffold is a feasible and safe regenerative approach for chronic wounds, associated with substantial wound area reduction, high rates of complete closure, significant improvements in wound status, systemic inflammatory and nutritional markers, and patient-reported quality of life. Because the study lacked a concurrent control group, these results should be interpreted as evidence of feasibility and safety rather than of efficacy, and require confirmation in an adequately powered randomised controlled trial.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.